Company profile for Biosplice

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. From our foundational discoveries in Want pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, our ...
Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. From our foundational discoveries in Want pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, our focus is on the realization of new, potentially curative therapies for patients by selectively reprogramming cellular behavior.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9360 Towne Centre Drive, San Diego, CA 92121
Telephone
Telephone
+1 858 926 2900
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/09/3146697/0/en/Biosplice-Therapeutics-Announces-First-Patient-Dosed-in-NCI-Sponsored-Clinical-Trial-of-Cirtuvivint-in-Acute-Myeloid-Leukemia-and-Myelodysplastic-Syndromes.html

GLOBENEWSWIRE
09 Sep 2025

https://www.globenewswire.com/news-release/2025/05/01/3072165/0/en/Biosplice-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-Cirtuvivint-for-Advanced-Soft-Tissue-Sarcomas.html

GLOBENEWSWIRE
01 May 2025

https://www.globenewswire.com/news-release/2024/09/12/2945069/0/en/Biosplice-Therapeutics-Announces-Initiation-of-Acute-Myeloid-Leukemia-AML-and-Myelodysplastic-Syndromes-MDS-Trial-Sponsored-by-the-National-Cancer-Institute-NCI.html

GLOBENEWSWIRE
12 Sep 2024

https://www.contractpharma.com/contents/view_breaking-news/2024-06-13/biosplice-novo-nordisk-partner-to-develop-drug-candidates-for-treatment-of-diabetes/?widget=listSection

CONTRACT PHARMA
13 Jun 2024

https://endpts.com/biosplice-searches-for-a-path-forward-after-osteoarthritis-drug-fails-late-stage-study/

Jared Whitlock ENDPTS
22 Apr 2024

https://www.globenewswire.com/news-release/2024/04/18/2865193/0/en/Biosplice-Announces-Upcoming-Presentation-of-Successful-OA-07-Phase-3-Long-Term-Structure-and-Pain-Function-Results-for-Lorecivivint-for-Treatment-of-Knee-Osteoarthritis-at-OARSI-C.html

GLOBENEWSWIRE
18 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty